Tweetovi

Blokirali ste korisnika/cu @justin_klee

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @justin_klee

  1. proslijedio/la je Tweet
    4. velj

    Welcome to the team as Amylyx' CFO, Jeff Trigilio! Jeff's leadership and financial acumen will be essential as we continue our mission to develop new treatments for and 's disease and bring them to patients and families as rapidly as we can.

    Poništi
  2. proslijedio/la je Tweet
    1. sij
    Poništi
  3. proslijedio/la je Tweet
    20. pro 2019.

    A very nice obituary about a best friend and colleague, Dr. Rob Moir, who first joined my lab in 1993 at Mass General Hospital, and changed the way we think about Alzheimer's disease. Thank you for a wonderful tribute to Rob.

    Poništi
  4. proslijedio/la je Tweet
    20. pro 2019.

    Remembering a best friend and brilliant colleague, Dr Rob Moir. Deepest condolences to his family and to the many friends who love him. And, thank you, Sharon for this tribute Unorthodox Alzheimer’s researcher Robert Moir dies at age 58

    Poništi
  5. 17. pro 2019.

    And thank you for your incredible leadership, passion, and relentless pursuit of new treatments and improvements in care for people with

    Poništi
  6. proslijedio/la je Tweet

    An experimental drug slowed the paralyzing march of Lou Gehrig’s disease in a clinical trial, according to researchers who say the results are a fresh sign that recent insights into the condition may soon bring new medicines.

    Poništi
  7. 17. pro 2019.

    Thank you so much for believing in us from the very start, and for all of your support over so many years!! Thrilled to have the opportunity to help people with ALS and so excited for the potential in Alzheimer's!

    Poništi
  8. proslijedio/la je Tweet
    17. pro 2019.

    Long live the bond of the fraternity brothers of as we worked together to make this happen and hopefully help ALS patients! Alzheimers's up next!

    Poništi
  9. 17. pro 2019.

    Thank you so much to everyone who has made this possible, especially the patients and families battling ALS every day - this is just the start, and we will continue to work tirelessly to advance treatments and care for ALS

    Poništi
  10. 17. pro 2019.

    Thank you very much for sharing our story! We're so thankful to everyone who has supported us on this journey, and so hopeful for what's to come

    Poništi
  11. 14. pro 2019.

    Deb is a phenomenal HR executive and we're so proud to have her join us. Her leadership will be a huge asset as we continue to build and grow, while always keeping focused on our mission

    Poništi
  12. proslijedio/la je Tweet
    30. lis 2019.

    In a recent interview with , cofounder and PI discussed Amylyx' mission to do right by patients if this trial is a success and the impact of a partnership between industry and academia. Read more:

    Poništi
  13. proslijedio/la je Tweet
    18. lis 2019.

    Congratulations to Principal Investigator on this incredible recognition for all of your efforts in the community.

    Poništi
  14. proslijedio/la je Tweet
    5. lis 2019.

    We’re thrilled to announce the last participant has completed the planned 24 weeks of study treatment. "Thank you to the participants and site study teams who have made this work possible,” said Principle Investigator, .

    Poništi
  15. proslijedio/la je Tweet
    3. lis 2019.

    Today at , Principal Investigator of , , presented the novel features and design of the clinical trial. We’re proud to share nearly 90% of participants have elected to continue into the open label extension

    Poništi
  16. proslijedio/la je Tweet
    3. lis 2019.

    lessons from CENTAUR trial (): - Central IRB feasible - Loud and clear: pts value access to open label extension (OLE) after trial completion - OLE is feasible, adds value w/long term safety data for FDA

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    23. ruj 2019.

    We are encouraged by the new FDA guidance on – particularly that all trials should have open label extensions and not exclude standard of care. Exciting to see the FDA innovating on more patient-centric trials.

    Poništi
  18. proslijedio/la je Tweet
    19. ruj 2019.

    Heading to next week in ? Tom Holmes, Amylyx’ global head of supply chain and keynote speaker, will be sharing his insights on the reliability and security of internal and external supply chains. Hope to see you there!

    Poništi
  19. proslijedio/la je Tweet
    22. srp 2019.

    thank you again for an excellent interview and article on Amylyx's goals to help patients with neurodegenerative diseases, and how integral outsourcing is to achieving those goals

    Poništi
  20. proslijedio/la je Tweet

    ICYMI: Dr. Emily Plowman, one of our Clinical Management Grant awardees, & her colleague, Dr. James Wymer, found that a mild-intensity respiratory strength training program was safe & improved function in a person with early-stage .

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·